• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Recognized Consensus Standards

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

New Search Back To Search Results
Part B: Supplementary Information Sheet (SIS)
FR Recognition List Number 052 Date of Entry 07/15/2019 
FR Recognition Number 7-290
Standard
CLSI EP34 1st Edition
Establishing and Verifying an Extended Measuring Interval Through Specimen Dilution and Spiking
Scope/Abstract
EP34 provides recommendations for establishing a dilution scheme to be used for patient specimens that contain measurand concentrations in the extended measuring interval above a measurement procedure's upper limit of quantitation.

Guidance is provided on determining, validating, and verifying the appropriate diluent and dilution ratio to be used for such specimens. This guideline also covers creating spiked samples for use during dilution recovery studies and using spiking to determine the suitability of a sample matrix for dilution recovery studies. The intended users of this guideline are manufacturers of in vitro diagnostic tests and medical laboratory scientists, directors, and pathologists.
Extent of Recognition
Partial recognition. The following part(s) of the standard is (are) not recognized:
Chapter 2: Establishing an Extended Measuring Interval Through Specimen Dilution and Spiking
Rationale for Recognition
This standard is relevant to medical devices and is recognized on its scientific and technical merit and/or because it supports existing regulatory policies.

Standard is recognized on a scientific basis: device performance. This standard conflicts with an existing regulation.

Chapter 2 does not satisfy the requirement for analytical performance characteristics under 21 CFR 809.10(b)(12) Specific Performance Characteristics and 21 CFR 807.87 because it describes requirements for establishing the extended measuring interval at research and development stage and not for submitters of premarket submissions.
Public Law, CFR Citation(s) and Procode(s)*
21 CFR 809.10(b)(12)
21 CFR 807.87
FDA Technical Contacts
 Stephen Lovell
  FDA/OC/CDRH/OPEQ/OIDRH/DMD/
  301-796-6968
  Stephen.Lovell@fda.hhs.gov
 Marina V. Kondratovich
  FDA/OC/CDRH/OPEQ/OIDRH/
  301-796-6036
  marina.kondratovich@fda.hhs.gov
 Elizabeth Stafford
  FDA/OC/CDRH/OPEQ/OIDRH/DIHD/IMFB/
  301-796-6184
  elizabeth.stafford@fda.hhs.gov
Standards Development Organization
CLSI Clinical Laboratory Standards Institute https://clsi.org/
FDA Specialty Task Group (STG)
InVitro Diagnostics
*These are provided as examples and others may be applicable.
-
-